21/07/2022

BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age

Abstract

BACKGROUND

Limited evidence is available on the real-world effectiveness of the BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) and specifically against infection with the omicron variant among children 5 to 11 years of age.

Matéria original

Anterior

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
Próxima

Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age